Literature DB >> 6166632

Molecular analysis of the beta-thalassemia phenotype associated with inheritance of hemoglobin E (alpha 2 beta2(26)Glu leads to Lys).

E J Benz, B W Berman, B L Tonkonow, E Coupal, T Coates, L A Boxer, A Altman, J G Adams.   

Abstract

Inheritance of the gene for betaE-globin is associated with hypochromia and microcytosis, reminiscent of typical heterozygous beta-thalassemia. Patients with hemoglobin (Hb)E-beta-thalassemia exhibit clinical phenotypes of severe beta-thalassemia, a circumstance not encountered in other compound heterozygous states for structural beta-chain mutations and beta-thalassemia. We have analyzed the kinetics of globin synthesis and the levels of globin messenger (m) RNA accumulation in patients with Hb E-beta-thalassemia and Hb E trait. The initial rate of beta-globin synthesis (betaE/alpha=0.20-0.34) was less than expected on the basis of gene dosage, or comparable studies of other compound heterozygous states for beta-thalassemia and structurally abnormal beta-chains. betaE-globin synthesis was not only reduced during short-term incubations (1-5 min), but also remained relatively unchanged during long-term pulse or chase incubations up to 5h. Analysis of globin mRNA by cell-free translation and molecular hybridization confirmed that the unexpectedly low levels of betaE-globin synthesis were associated with comparable reduction in the levels of beta-globin mRNA. In Hb E-beta-thalassemia the betaA + betaE (alpha globin nRNA ratio observed were substantially lower than those obtained from reticulocytes of patients with heterozygous beta-thalassemia, or Hb S-betaO-thalassemia, while in Hb E trait, the betaA + betaE/alpha mRNA ratio was in the ranged observed for beta-thalassemia trait. The betaE-globin gene specifies reduced accumulation of betaE-globin mRNA, a property characteristic of other forms of beta-thalassemia. The beta-thalassemia phenotype associated with inheritance of Hb E is thus determined at the level of beta-globin mRNA metabolism.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166632      PMCID: PMC370779          DOI: 10.1172/jci110226

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Clinical, hematologic and biosynthetic studies in sickle cell-betao-thalassemia: a comparison with sickle cell anemia.

Authors:  M H Steinberg; B J Dreiling
Journal:  Am J Hematol       Date:  1976       Impact factor: 10.047

Review 2.  The biosynthesis of hemoglobin.

Authors:  E J Benz; B G Forget
Journal:  Semin Hematol       Date:  1974-10       Impact factor: 3.851

3.  Defect in hemoglobin synthesis possibly due to a disturbed association.

Authors:  J Pagnier; H Wajcman; A Labie
Journal:  FEBS Lett       Date:  1974-09-01       Impact factor: 4.124

4.  Hemoglobin Rush (beta 101 (g3) glutamine): a new unstable hemoglobin causing mild hemolytic anemia.

Authors:  J G Adams; W P Winter; K Tausk; P Heller
Journal:  Blood       Date:  1974-02       Impact factor: 22.113

5.  Beta thalassemia and translation of globin messenger RNA.

Authors:  D G Nathan; H F Lodish; Y W Kan; D Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1971-10       Impact factor: 11.205

6.  beta-Thalassemia present in cis to a new beta-chain structural variant, Hb Vicksburg [beta 75 (E19)Leu leads to 0].

Authors:  J G Adams; M H Steinberg; M V Newman; W T Morrison; E J Benz; R Iyer
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

Review 7.  Pathogenesis of the thalassemia syndromes.

Authors:  E J Benz; B G Forget
Journal:  Pathobiol Annu       Date:  1980

8.  Splenic sequestration and ineffective erythropoiesis in hemoglobin E-beta-thalassemia disease.

Authors:  F B Ruymann; L A Popejoy; R B Brouillard
Journal:  Pediatr Res       Date:  1978-10       Impact factor: 3.756

9.  Hemoglobin messenger RNA from human bone marrow. Isolation and translation in homozygous and heterozygous beta-thalassemia.

Authors:  A W Nienhuis; P H Canfield; W F Anderson
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

10.  Defect in messenger RNA for human hemoglobin synthesis in beta thalassemia.

Authors:  E J Benz; B G Forget
Journal:  J Clin Invest       Date:  1971-12       Impact factor: 14.808

View more
  8 in total

1.  Effects of hemin on a lymphoblastoid cell line that expresses the human epsilon- and gamma-globin genes.

Authors:  G Brewer; L S Hnilica; R C Briggs
Journal:  Mol Cell Biochem       Date:  1985-09       Impact factor: 3.396

2.  Hemoglobin E in Europeans: further evidence for multiple origins of the beta E-globin gene.

Authors:  H H Kazazian; P G Waber; C D Boehm; J I Lee; S E Antonarakis; V F Fairbanks
Journal:  Am J Hum Genet       Date:  1984-01       Impact factor: 11.025

Review 3.  The thalassemias: molecular mechanisms of human genetic disease.

Authors:  R A Spritz; B G Forget
Journal:  Am J Hum Genet       Date:  1983-05       Impact factor: 11.025

4.  Evidence for multiple origins of the beta E-globin gene in Southeast Asia.

Authors:  S E Antonarakis; S H Orkin; H H Kazazian; S C Goff; C D Boehm; P G Waber; J P Sexton; H Ostrer; V F Fairbanks; A Chakravarti
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

5.  Instability of beta E-messenger RNA during erythroid cell maturation in hemoglobin E homozygotes.

Authors:  J Traeger; P Winichagoon; W G Wood
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

6.  Hemoglobin E in Indochinese refugees.

Authors:  T M Cunningham
Journal:  West J Med       Date:  1982-09

Review 7.  Thalassemic hemoglobinopathies.

Authors:  M H Steinberg; J G Adams
Journal:  Am J Pathol       Date:  1983-12       Impact factor: 4.307

8.  Two missense mutations in the beta-globin gene can cause severe beta thalassemia. Hemoglobin Medicine Lake (beta 32[B14]leucine-->glutamine; 98 [FG5] valine-->methionine).

Authors:  M B Coleman; Z H Lu; C M Smith; J G Adams; A Harrell; M Plonczynski; M H Steinberg
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.